Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.59 |
| ▸ | CTSB | P07858 | 2/20 | 0.59 |
| ▸ | DPP4 | P27487 | 1/20 | 0.57 |
| ▸ | DPP3 | Q9NY33 | 5/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31463314 | 0.89 | DPP4 (0.61) | CAPN1CTSBDPP4DPP3OPRM1 | |
| SCHEMBL29842186 | 0.88 | DPP3 (0.65) | DPP4DPP3 | |
| SCHEMBL31072081 | 0.87 | DPP3 (0.68) | CAPN1CTSBDPP3OPRM1 | |
| SCHEMBL31499422 | 0.86 | DPP3 (0.57) | CAPN1CTSBDPP4DPP3OPRM1 | |
| SCHEMBL29498733 | 0.85 | DPP3 (0.63) | DPP4DPP3 | |
| SCHEMBL30050936 | 0.85 | DPP3 (0.69) | DPP4DPP3OPRM1 | |
| Endomorphin-1 SCHEMBL21811384 | 0.84 | — | — | |
| SCHEMBL20749886 | 0.84 | OPRM1 (0.63) | DPP3OPRM1 | |
| Endomorphin-1 SCHEMBL29577928 | 0.84 | — | — | |
| Endomorphin-1 SCHEMBL29390342 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210106690-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2021-04-15 | — | — | US | disclosed |
| US-10603386-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| EP-3228325-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | Mersana Therapeutics, Inc. (US) | 2017-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | CAPN1 2306/4885CTSB 2821/4885DPP4 3512/4885 |
| US-20210106690-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | CAPN1 2487/4885CTSB 2880/4885DPP4 3319/4885 |
| US-10603386-B2 | Protein-polymer-drug conjugates | PBRM1, CLTB, BRAP | CAPN1 2660/4885CTSB 3014/4885DPP4 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.